1-Hour Program

See Credit Details Below

Overview

Whether you are acquiring a company or its assets or divesting a portion of your business, if you are involved in mergers and acquisitions relating to  pharmaceutical products, biologics, medical devices, diagnostics or similar assets, it is important to understand the products, their regulatory environment, the intellectual property landscape, the supply chain and other market factors.  These deals often involve a high degree of complexity and, typically, a host of third party relationships that require careful due diligence.  The transaction may involve not only a purchase and sale agreement but also other related agreements (e.g., license agreements, manufacturing agreements and transition services agreements).  In order to ensure effective transfer of the products and ensure business continuity, focus on the post-closing period can be critical.  The risks and rewards in these transaction can both be high —relating to clinical success, a difficult regulatory environment, complicated intellectual property landscapes, life cycle management, commercial viability, potential liabilities and employee matters.  Learn how to address these issues to better realize the business objectives and value of your next life sciences M&A deal.   

Please join Catherine J. Dargan (M&A partner) and Amy L. Toro (Life Sciences Technology Transactions partner) of Covington & Burling LLP for a One-Hour Briefing when they discuss special considerations that frequently arise in life sciences M&A deals, including how to: 

  • Implement effective deal structuring mechanisms (e.g., deferred payment provisions, key transitional agreements, risk sharing approaches and special covenants and indemnities)
  • Handle unique challenges relating to product acquisition and divestiture deals
  • Create effective key ancillary agreements
  • Identify and manage key due diligence concerns to mitigate risk and preserve post-closing flexibility
  • Anticipate and resolve post-closing matters including product transfer, supply continuity, employee retention and technology transfer

Credit Details